Topotecan treatment of adults with primary malignant glioma

Henry S. Friedman, Tracy Kerby, Scott Fields, Janice E. Zilisch, David Graden, Roger E. McLendon, Peter J. Houghton, Susan Arbuck, Ilkcan Cokgor, Allan H. Friedman

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


BACKGROUND. Topotecan activity was evaluated for the treatment of malignant glioma. METHODS. Sixty-three patients with newly diagnosed (n = 25) or recurrent (n = 38) malignant glioma were treated with topotecan {AU: Please verify all dosages here and throughout text.}at a dose of 2.6 mg/m2 over a 72-hour period weekly. Recurrent tumors included glioblastoma multiforme (GBM) (n = 28) and anaplastic astrocytoma (AA) (n = 10). Newly diagnosed tumors included GBM (n = 14), AA (n = 8), and anaplastic oligodendroglioma (n = 3). RESULTS. Partial responses were observed in 2 of 14 evaluable patients with newly diagnosed GBM, 1 of 8 patients with newly diagnosed AA, 3 of 10 patients with recurrent AA, and none of 28 patients with recurrent GBM. Four patients with recurrent AA and 7 patients with recurrent GBM demonstrated stable disease (range, 8-52 weeks; median, 21 weeks). Toxicity was limited to infrequent National Cancer Institute Common Toxicity Criteria Grade 3 myelosuppression. CONCLUSIONS. These results suggest that topotecan has modest activity against malignant glioma and continued evaluation of its effectiveness may be warranted when alternative schedules or combination regimens are used.

Original languageEnglish (US)
Pages (from-to)1160-1165
Number of pages6
Issue number5
StatePublished - 1999
Externally publishedYes


  • Brain tumor
  • Chemotherapy
  • Glioma
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Topotecan treatment of adults with primary malignant glioma'. Together they form a unique fingerprint.

Cite this